Tenax Therapeutics Participates in Notable Healthcare Conference
Tenax Therapeutics, Inc. (NASDAQ: TENX), a prominent player in the pharmaceutical industry focused on groundbreaking cardiopulmonary therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. This significant event is set to occur virtually, providing a platform for the Company to showcase its innovations and mission to address critical health challenges.
Details of the Upcoming Presentation
The Company has outlined the particulars of its presentation, slated for April 7, 2025, at 3:45 p.m. ET. The corporate presentation format promises to be engaging, with key insights shared by the leadership team. Chris Giordano, Tenax's President and Chief Executive Officer, will take the lead along with Dr. Stuart Rich, the Chief Medical Officer, and Doug Randall, the Chief Business Officer, bringing their expertise to the forefront of the discussion.
Innovative Focus on Pulmonary Hypertension
Tenax Therapeutics is particularly recognized for its commitment to developing new therapies to combat pulmonary hypertension, especially the PH-HFpEF variant, which is the most common form of this serious condition. Currently, there are no approved treatments available, making the Company's work vital in advancing healthcare solutions.
Live Webcast and Accessibility
For those interested in following the presentation, Tenax Therapeutics offers a live and archived webcast of the event on their investor relations webpage. This will allow investors and stakeholders to connect and gain insights even after the live presentation has concluded. Such accessibility is pivotal for fostering transparency and engagement within the financial and healthcare communities.
About Tenax Therapeutics' Mission
The mission of Tenax Therapeutics extends beyond simple product development. The Company aims to revolutionize cardiopulmonary care by leveraging clinical insights and innovative scientific approaches. By focusing on conditions that currently lack effective treatment options, Tenax is positioned to make a meaningful impact in the lives of patients worldwide.
Continued Commitment to Innovation
As a Phase 3 developmental-stage pharmaceutical company, Tenax's dedication to innovation is evident in its ongoing research and development efforts. The Company not only focuses on expanding its product pipeline but also emphasizes comprehensive clinical studies to ensure the safety and efficacy of its therapies.
Contact Information for Investor Inquiries
For further inquiries, Tenax Therapeutics has designated Merrill Barrett from Argot Partners to manage investor relations. Those interested can reach out via email at tenax@argotpartners.com, ensuring streamlined communication and support for interested investors and media.
Frequently Asked Questions
What is Tenax Therapeutics participating in?
Tenax Therapeutics is participating in the 24th Annual Needham Virtual Healthcare Conference to present their insights and developments in cardiopulmonary therapies.
Who are the key speakers at the conference?
The key speakers include Chris Giordano, President & CEO, Stuart Rich, M.D., Chief Medical Officer, and Doug Randall, Chief Business Officer.
When will the presentation take place?
The presentation is scheduled for April 7, 2025, at 3:45 p.m. ET.
How can one access the presentation?
Audience members can access the live and archived webcast on the Tenax investor relations webpage.
What does Tenax Therapeutics focus on?
Tenax Therapeutics specializes in developing novel therapies for cardiopulmonary conditions, particularly targeting pulmonary hypertension.
